Literature DB >> 26562506

Structural Stability and Local Dynamics in Disease-Causing Mutants of Human Apolipoprotein A-I: What Makes the Protein Amyloidogenic?

Madhurima Das1, Christopher J Wilson2, Xiaohu Mei1, Thomas E Wales2, John R Engen2, Olga Gursky3.   

Abstract

ApoA-I, the major protein of plasma high-density lipoprotein, removes cellular cholesterol and protects against atherosclerosis. ApoA-I mutations can cause familial amyloidosis, a life-threatening disease wherein N-terminal protein fragments form fibrils in vital organs. To unveil the protein misfolding mechanism and to understand why some mutations cause amyloidosis while others do not, we analyzed the structure, stability, and lipid-binding properties of naturally occurring mutants of full-length human apoA-I causing either amyloidosis (G26R, W50R, F71Y, and L170P) or aberrant lipid metabolism (L159R). Global and local protein conformation and dynamics in solution were assessed by circular dichroism, fluorescence, and hydrogen-deuterium exchange mass spectrometry. All mutants showed increased deuteration in residues 14-22, supporting our hypothesis that decreased protection of this major amyloid "hot spot" can trigger protein misfolding. In addition, L159R showed local helical unfolding near the mutation site, consistent with cleavage of this mutant in plasma to generate the labile 1-159 fragment. Together, the results suggest that reduced protection of the major amyloid "hot spot", combined with the structural integrity of the native helix bundle conformation, shifts the balance from protein clearance to β-aggregation. A delicate balance between the overall structural integrity of a globular protein and the local destabilization of its amyloidogenic segments may be a fundamental determinant of this and other amyloid diseases. Furthermore, mutation-induced conformational changes observed in the helix bundle, which comprises the N-terminal 75% of apoA-I, and its flexible C-terminal tail suggest the propagation of structural perturbations to distant sites via an unexpected template-induced ensemble-based mechanism, challenging the classical structure-based view.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  familial amyloidosis and atherosclerosis; hydrogen–deuterium exchange mass spectrometry; protein stability and misfolding; protein–lipid interactions; transmission of conformational changes

Mesh:

Substances:

Year:  2015        PMID: 26562506      PMCID: PMC4744490          DOI: 10.1016/j.jmb.2015.10.029

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  49 in total

Review 1.  Structural models of human apolipoprotein A-I: a critical analysis and review.

Authors:  C G Brouillette; G M Anantharamaiah; J A Engler; D W Borhani
Journal:  Biochim Biophys Acta       Date:  2001-03-30

2.  Comparative calorimetric study of non-amyloidogenic and amyloidogenic variants of the homotetrameric protein transthyretin.

Authors:  V L Shnyrov; E Villar; G G Zhadan; J M Sanchez-Ruiz; A Quintas; M J Saraiva; R M Brito
Journal:  Biophys Chem       Date:  2000-12-15       Impact factor: 2.352

Review 3.  The effects of altered apolipoprotein A-I structure on plasma HDL concentration.

Authors:  Mary G Sorci-Thomas; Michael J Thomas
Journal:  Trends Cardiovasc Med       Date:  2002-04       Impact factor: 6.677

4.  Proteolytic degradation and impaired secretion of an apolipoprotein A-I mutant associated with dominantly inherited hypoalphalipoproteinemia.

Authors:  D C McManus; B R Scott; V Franklin; D L Sparks; Y L Marcel
Journal:  J Biol Chem       Date:  2001-04-05       Impact factor: 5.157

5.  The extreme N-terminal region of human apolipoprotein A-I has a strong propensity to form amyloid fibrils.

Authors:  Emi Adachi; Asako Kosaka; Kohei Tsuji; Chiharu Mizuguchi; Hiroyuki Kawashima; Akira Shigenaga; Kohjiro Nagao; Kenichi Akaji; Akira Otaka; Hiroyuki Saito
Journal:  FEBS Lett       Date:  2013-12-05       Impact factor: 4.124

6.  Apolipoprotein A-1-derived amyloid in atherosclerotic plaques of the human aorta.

Authors:  G I Mucchiano; B Häggqvist; K Sletten; P Westermark
Journal:  J Pathol       Date:  2001-02       Impact factor: 7.996

Review 7.  The ensemble nature of allostery.

Authors:  Hesam N Motlagh; James O Wrabl; Jing Li; Vincent J Hilser
Journal:  Nature       Date:  2014-04-17       Impact factor: 49.962

8.  Binding of human apoA-I[K107del] variant to TG-rich particles: implications for mechanisms underlying hypertriglyceridemia.

Authors:  Irina N Gorshkova; Xiaohu Mei; David Atkinson
Journal:  J Lipid Res       Date:  2014-06-11       Impact factor: 5.922

9.  Amyloidogenic mutations in human apolipoprotein A-I are not necessarily destabilizing - a common mechanism of apolipoprotein A-I misfolding in familial amyloidosis and atherosclerosis.

Authors:  Madhurima Das; Xiaohu Mei; Shobini Jayaraman; David Atkinson; Olga Gursky
Journal:  FEBS J       Date:  2014-04-28       Impact factor: 5.542

10.  Microenvironmentally controlled secondary structure motifs of apolipoprotein A-I derived peptides.

Authors:  Paola Mendoza-Espinosa; Danai Montalvan-Sorrosa; Victor García-González; Abel Moreno; Rolando Castillo; Jaime Mas-Oliva
Journal:  Mol Cell Biochem       Date:  2014-04-20       Impact factor: 3.396

View more
  17 in total

1.  Structural stability and local dynamics in disease-causing mutants of human apolipoprotein a-I: what makes the protein amyloidogenic?

Authors:  Madhurima Das; Christopher J Wilson; Xiaohu Mei; Thomas Wales; John R Engen; Olga Gursky
Journal:  Amyloid       Date:  2016-12-31       Impact factor: 7.141

2.  Structural Basis for Lipid Binding and Function by an Evolutionarily Conserved Protein, Serum Amyloid A.

Authors:  Nicholas M Frame; Meera Kumanan; Thomas E Wales; Asanga Bandara; Marcus Fändrich; John E Straub; John R Engen; Olga Gursky
Journal:  J Mol Biol       Date:  2020-02-06       Impact factor: 5.469

Review 3.  [Inborn errors of high-density lipoprotein metabolism].

Authors:  Arnold von Eckardstein
Journal:  Internist (Berl)       Date:  2019-12       Impact factor: 0.743

4.  A Conservative Point Mutation in a Dynamic Antigen-binding Loop of Human Immunoglobulin λ6 Light Chain Promotes Pathologic Amyloid Formation.

Authors:  Daniele Peterle; Elena S Klimtchuk; Thomas E Wales; Florian Georgescauld; Lawreen H Connors; John R Engen; Olga Gursky
Journal:  J Mol Biol       Date:  2021-10-19       Impact factor: 5.469

Review 5.  Advances in Hydrogen/Deuterium Exchange Mass Spectrometry and the Pursuit of Challenging Biological Systems.

Authors:  Ellie I James; Taylor A Murphree; Clint Vorauer; John R Engen; Miklos Guttman
Journal:  Chem Rev       Date:  2021-09-07       Impact factor: 72.087

Review 6.  Dynamic protein structures in normal function and pathologic misfolding in systemic amyloidosis.

Authors:  Emily Lewkowicz; Olga Gursky
Journal:  Biophys Chem       Date:  2021-10-14       Impact factor: 3.628

Review 7.  Diagnosis and treatment of high density lipoprotein deficiency.

Authors:  Ernst J Schaefer; Pimjai Anthanont; Margaret R Diffenderfer; Eliana Polisecki; Bela F Asztalos
Journal:  Prog Cardiovasc Dis       Date:  2016-08-24       Impact factor: 8.194

8.  Site-specific 5-hydroxytryptophan incorporation into apolipoprotein A-I impairs cholesterol efflux activity and high-density lipoprotein biogenesis.

Authors:  Maryam Zamanian-Daryoush; Valentin Gogonea; Anthony J DiDonato; Jennifer A Buffa; Ibrahim Choucair; Bruce S Levison; Randall A Hughes; Andrew D Ellington; Ying Huang; Xinmin S Li; Joseph A DiDonato; Stanley L Hazen
Journal:  J Biol Chem       Date:  2020-02-25       Impact factor: 5.157

Review 9.  Amyloidosis in Heart Failure.

Authors:  Sandra Ihne; Caroline Morbach; Laura Obici; Giovanni Palladini; Stefan Störk
Journal:  Curr Heart Fail Rep       Date:  2019-12

10.  Effects of Disease-Causing Mutations on the Conformation of Human Apolipoprotein A-I in Model Lipoproteins.

Authors:  Christopher J Wilson; Madhurima Das; Shobini Jayaraman; Olga Gursky; John R Engen
Journal:  Biochemistry       Date:  2018-07-13       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.